AKTX
Income statement / Annual
Last year (2024), Akari Therapeutics, Plc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Akari Therapeutics, Plc's net income was -$19.79 M.
See Akari Therapeutics, Plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$19.21 K
|
$35.85 K
|
$42.40 K
|
$39.77 K
|
$10.16 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$19.21 K
|
-$35.85 K
|
-$42.40 K
|
-$39.77 K
|
-$10.16 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$6.98 M
|
$8.02 M
|
$9.56 M
|
$9.13 M
|
$12.19 M
|
$16.65 M
|
$15.59 M
|
$23.29 M
|
$17.31 M
|
$5.80 M
|
| General & Administrative Expenses |
$9.66 M
|
$11.36 M
|
$13.53 M
|
$8.08 M
|
$9.16 M
|
$0.00
|
$10.90 M
|
$11.67 M
|
$9.94 M
|
$5.50 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.66 M
|
$11.36 M
|
$13.53 M
|
$8.08 M
|
$9.16 M
|
$8.20 M
|
$10.90 M
|
$11.67 M
|
$9.94 M
|
$5.50 M
|
| Other Expenses |
$5.00 M
|
-$2.57 M
|
$0.00
|
$0.00
|
-$3.37 M
|
$0.00
|
-$2.68 M
|
-$13.39 K
|
-$43.97 K
|
-$44.22 K
|
| Operating Expenses |
$21.64 M
|
$16.81 M
|
$23.09 M
|
$17.21 M
|
$17.98 M
|
$24.85 M
|
$23.80 M
|
$34.96 M
|
$27.25 M
|
$11.30 M
|
| Cost And Expenses |
$21.64 M
|
$16.81 M
|
$23.09 M
|
$17.21 M
|
$17.98 M
|
$24.87 M
|
$23.80 M
|
$34.96 M
|
$27.25 M
|
$11.30 M
|
| Interest Income |
$8.00 K
|
$82.00 K
|
$45.94 K
|
$10.60 K
|
$13.00 K
|
$5.00 K
|
$222.26 K
|
$175.39 K
|
$143.20 K
|
$20.71 K
|
| Interest Expense |
-$244.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.15 M
|
$3.05 M
|
| Depreciation & Amortization |
$14.00 K
|
$4.00 K
|
$4.00 K
|
$4.13 K
|
$8.91 K
|
$19.21 K
|
$35.85 K
|
$42.40 K
|
$39.77 K
|
$10.16 K
|
| EBITDA |
-$19.53 M |
-$16.80 M |
-$23.08 M |
-$17.21 M |
-$17.97 M |
-$24.73 M |
-$16.43 M |
-$35.36 M |
-$27.25 M |
-$19.28 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.85 M
|
$6.80 M
|
$5.34 M
|
-$210.10 K
|
$899.36 K
|
$116.92 K
|
-$507.93 K
|
$2.38 M
|
$9.11 M
|
-$14.72 M
|
| Income Before Tax |
-$19.79 M
|
-$10.01 M
|
-$17.75 M
|
-$17.42 M
|
-$17.08 M
|
-$24.75 M
|
-$23.50 M
|
-$32.57 M
|
-$18.14 M
|
-$45.32 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$7.91 M
|
-$3.55 M
|
-$4.65 M
|
-$43.97 K
|
$0.00
|
| Net Income |
-$19.79 M
|
-$10.01 M
|
-$17.75 M
|
-$17.42 M
|
-$17.08 M
|
-$16.85 M
|
-$19.95 M
|
-$27.92 M
|
-$18.14 M
|
-$45.32 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1660 |
-200 |
-220 |
-820 |
-1560 |
-2380 |
-2520 |
-4480 |
-3080 |
-10640 |
| EPS Diluted |
-1660 |
-200 |
-220 |
-820 |
-1120 |
-2380 |
-2520 |
-4480 |
-3080 |
-10640 |
| Weighted Average Shares Out |
$11.94 K
|
$4.89 K
|
$3.12 K
|
$2.15 K
|
$1.12 K
|
$915.00
|
$790.00
|
$623.00
|
$588.00
|
$426.00
|
| Weighted Average Shares Out Diluted |
$11.94 K
|
$4.89 K
|
$3.12 K
|
$2.15 K
|
$1.58 K
|
$915.00
|
$790.00
|
$623.00
|
$588.00
|
$426.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
